Recent studies have centered on the intersection of GLP-1|GIP|glucagon receptor activator therapies and dopaminergic signaling. While GIP stimulators are increasingly employed for treating type 2 T2DM, their emerging impacts on motivation circuits, specifically mediated by dopaminergic systems, are attracting considerable focus. This report provide